
    
      Patients with Severe Pneumonia caused by SARS-CoV-2 infection are enrolled to the study.
      Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four
      times intravenously. Safety and efficacy of AD-MSCs are evaluated for 12 weeks after first
      administer.
    
  